Ning Dong

Ning Dong

Auto-generated profile, based on publicly available information

Ning Dong

Department of Malignant Hematology Moffitt Cancer Center Tampa Florida USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
NDNing Dong
Ning Dong
FTFranco Castillo Tokumori
Franco Castillo Tokumori
LILeidy Isenalumhe
Leidy Isenalumhe
YZYumeng Zhang
Yumeng Zhang
ATAnkita Tandon
Ankita Tandon
LSLubomir Sokol
Lubomir Sokol

18 January 2024 in eJHaem
Verified
Journal Article
Open access
NDNing Dong
Ning Dong
HZHailing Zhang
Hailing Zhang
JSJinming Song
Jinming Song
JMJamila Mammadova
Jamila Mammadova
BSBijal Shah
Bijal Shah
JCJulio Chavez
Julio Chavez

5 March 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NDNing Dong
Ning Dong
LLLucía Rubio Lopes-Garcia
Lucía Rubio Lopes-Garcia
DVDavid Viñal
David Viñal
CBChristina Bachmeier
Christina Bachmeier
BSBijal D. Shah
Bijal D. Shah
JCJulio C. Chavez
Julio C. Chavez
CD19-directed chimeric antigen receptor (CAR) T cell (CAR-T) therapy with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) are approved for the treatment of relapsed or refractory large B cell lymphoma (LBCL), including de novo diffuse LBCL (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (tFL). Transformed nonfollicular lymphomas (tNFLs), including transformed marginal zone lymphoma (tMZL) and transformed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were not included in their respective pivotal studies. This study was conducted to evaluate the outcomes of axi-cel and tisa-cel in tNFL patients, including those who received ibrutinib concomitantly through apheresis, lymphodepletion, and CAR-T infusion. This single-center retrospective study included all patients with tCLL/SLL, tMZL, tFL, and DLBCL/PMBCL treated with CAR-T therapy outside of a clinical trial setting from November 2017 to May 2021 at Moffitt Cancer Center, Tampa, Florida. We analyzed and compared outcomes in patients with tCLL/SLL or tMZL and patients with DLBCL/tFL. The study included 134 patients who received a total of 136 CAR-T treatments (111 with axi-cel and 25 with tisa-cel). Ninety patients had de novo DLBCL/PMBCL, 23 had tFL, and 21 had tNFL (12 with tMZL and 9 with tCLL/SLL). The overall response and complete response rates were 66.7% and 55.6%, respectively, for tCLL/SLL and 92.9% and 71.4% for tMZL. The overall response and complete response rates were not different between tNFL and DLBCL/tFL (P = .92 and .81, respectively). At a median follow-up of 21.3 months, the median progression-free survival (PFS) for tCLL/SLL was 5.4 months (95% confidence interval [CI], .8 month to not assessable [NA]); for tMZL, the median PFS was not reached (NR) (95% CI, 2.3 months to NA); and for DLBCL/tFL, the median PFS was 14.3 months (95% CI, 5.6 months to NA) (P = .58). The estimated 1-year PFS rate was 29.6% (95% CI, 5.2% to 60.7%) for tCLL/SLL, 50.0% (95% CI, 22.9% to 72.2%) for tMZL, 42.7% (95% CI, 22.4% to 61.6%) for tNFL, and 53.0% (95% CI, 42.3% to 62.5%) for DLBCL/tFL. The median overall survival was NR (95% CI, 9.2 months to NA) for tCLL/SLL, 27.1 months (95% CI, 8.5 months to NA) for tMZL, and NR (95% CI, 17.4 months to NA) for DLBCL/tFL (P = .79). Compared to the DLBCL/tFL cohort, tNFL patients were more likely to develop immune effector cell-associated neurologic syndrome (ICANS) and to receive tocilizumab (P = .04 and .01, respectively, after controlling for CAR-T product) and with a possibly higher incidence of grade ≥3 cytokine release syndrome (CRS) (P = .07). Two patients in the tNFL cohort died of treatment-related toxicity after receiving axi-cel. Six tNFL patients received ibrutinib concurrently with tisa-cel, with 1 case of grade ≥3 CRS/ICANS that rapidly resolved and no other severe toxicities. Our case series supports the use of CD19 CAR-T therapy in relapsed/refractory tCLL/SLL and tMZL. The concurrent use of ibrutinib and tisa-cel in tNFL was associated with manageable toxicity in tNFL.

1 June 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
JSJinming Song
Jinming Song
HZHailing Zhang
Hailing Zhang
NDNing Dong
Ning Dong
XZXiaohui Zhang
Xiaohui Zhang
MHMohammad Hussaini
Mohammad Hussaini
LZLing Zhang
Ling Zhang

3 August 2026 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
HSHayder Saeed
Hayder Saeed
MVMelanie Mediavilla Varela
Melanie Mediavilla Varela
ESEva Sahakian
Eva Sahakian
MNMahrukh Naqvi
Mahrukh Naqvi
QMQianxing Mo
Qianxing Mo
JPJavier Pinilla‐Ibarz
Javier Pinilla‐Ibarz